Introduction Robotically guided radiofrequency (RF) ablation offers greater catheter stability that may improve lesion depth. We performed a non-randomised comparison of patients undergoing ventricular tachycardia (VT) ablation either manually or robotically using the Hansen Sensei system for recurrent implantable defibrillator (ICD) therapy. Methods Patients with infarct-related scar underwent VT ablation using the Hansen system to assess feasibility compared with patients undergoing manual VT ablation during a similar time period. Power delivery during robotic ablation was restricted to 30 W at 60 s. VT inducibility was checked at the end of the procedure. Pre-ablation ICD therapy burdens over 6 months were compared with post-ablation therapy averaged to a 6-month period. Results Twelve consecutive patients who underwent robotic VT ablation were compared to 12 consecutive patients undergoing a manual ablation. Patient demographics and comorbidities were similar in the two groups. A higher proportion of robotic cases were urgent (9/12 (75 %)) vs. manual (4/12 (33 %)) (p=0.1). Post-ablation VT stimulation did not induce clinical VT in 11/12 (92 %) in each group. There were no periprocedural complications related to ablation delivery. Patients were followed up for approximately 2 years. Averaged over 6 months, robotic ICD therapy burdens fell from 32 (5-400) events to 2.5 (0-11) (p=0.015). Therapy burden fell from 14 (10-25) to 1 (0-5) (p=0.023) in the manual group. There was no difference in long-term outcome (p=0.60) and mortality (4/12 (33 %), p=1.0). Conclusion Robotically guided VT ablation is both feasible and safe when compared to manual ablation with good acute and long-term outcomes.
Introduction
Ventricular tachycardia (VT) remains a major cause of morbidity and mortality in patients with ischemic heart disease. Although implantable cardioverter-defibrillators (ICD) prevent sudden cardiac death, repeated device therapies have a major impact on quality of life [1] . Recurrent ICD therapies are associated with a worse prognosis [2] . VT ablation has been used to both reduce and prevent ICD therapy. However, despite the introduction of cardiac mapping systems, irrigated tip catheters and substrate-based ablation strategies, patients continue to experience on-going ICD therapies for VT recurrence in long-term follow-up [3] [4] [5] . Failure to achieve lesions with sufficient depth to target circuits near the epicardial surface is a potential cause for recurrent VT.
Robotically assisted ablation has been suggested as a method for increasing lesion depth, and the Hansen Sensei® X Robotic Catheter system (Hansen Medical Inc., Mountain View, CA, USA) has been shown to be feasible for use in cardiac ablation [6] . In brief, it comprises the physician's workstation, remote catheter manipulator (RCM) and a steerable guide catheter (Artisan™ Control Catheter). The movements of a joystick within the physician's workstation are transferred into movements of the RCM, a robot that controls pull wires within the steerable sheath. The tensile strength of the pull wires within the steerable sheath maintains its shape allowing improved catheter stability and increased lesion depth [7] .
In animal studies, we demonstrated that at equivalent ablation settings, a more rapid and greater reduction in local electrogram amplitude during robotic ablation compared with manual. Macroscopic examination of robotic lesions was also associated with greater lesion transmurality [8] .
The use of robotic catheter ablation in atrial-based arrhythmias is well described [9] [10] [11] [12] [13] . Feasibility in VT ablation has also been proposed [14] [15] [16] [17] . Robotic catheter ablation for scar-related VT offers an attractive strategy in trying to target channels with deeper lesions. There is also the added benefit of reduced operator radiation exposure for these long procedures.
This study aimed to assess the feasibility and safety of using the Sensei Robotic System to guide VT ablation in a series of patients with post infarct-related scar and be the first to compare acute and long-term outcome data to a cohort of patients who underwent manual ablation.
Methods

Patients
The departmental procedural database was reviewed to identify all patients who underwent post infarct scar-related VT ablation for recurrent ICD therapies using the Hansen Sensei Catheter Control System between January 2010 and January 2014. In the same time period that all robotic cases were identified, all manual ablations were also reviewed. These patients included those presenting acutely to our centre either directly or from neighbouring local hospitals or electively following assessment in ICD clinic. Patients were excluded if they were involved in any other VT ablation study or if they were followed up outside of our institution. Patients were also excluded if they failed to undergo a programmed electrical ventricular stimulation to assess inducibility post-ablation. Long-term outcome data was gathered from the patients' clinical case notes, or their ICD device downloads from clinic or remote monitoring. All patients included in this study signed an informed consent before the ablation procedure.
End points
The immediate ablation outcome was assessed with VT inducibility following programmed ventricular electrical stimulation. Patients were defined as non-inducible (group A), inducible for non-clinical VT (group B) and inducible for the clinical VT (group C).
Long-term outcomes were defined by the cumulative burden of appropriate ICD therapies (anti-tachycardia pacing (ATP)+shocks). This was assessed from 6-months pre-ablation and compared with the post-ablation therapy burden till their most recent device interrogation or redo procedure. ICDs were interrogated whenever symptoms suggested delivery of device therapy in addition to routine follow-up in ICD clinic and by remote follow-up. A 6-month proportion of each patient's total therapy burden during follow-up was calculated for each patient ((6/follow-up duration (months))×total therapies post-ablation) allowing direct comparison with the 6-month pre-ablative burden.
Electrophysiology study and mapping
A conventional electrophysiology recording system (BARD, LabSystem™ PRO Review Workstation, Lowell, MA, USA) and the CARTO XP ™ electro-anatomical mapping system (Biosense Webster Inc., Diamond Bar, CA, USA) were used in all cases. Procedures were performed either under conscious sedation or general anaesthesia. Patients were continuously monitored throughout the procedure by invasive systemic arterial pressure and non-invasive oxygen saturation. For systemic anticoagulation, repeat bolus injections of heparin based on the activated clotting time (ACT) measurements were given (target 300-350 s). A trans-septal puncture was performed from a right femoral venous access and a J-wire placed in the left upper pulmonary vein before the sheath was withdrawn into the right atrium. The irrigated Hansen Artisan sheath was loaded with an open-irrigated radiofrequency ablation catheter (Navistar ThermocoolTM, Biosense Webster Inc.) and introduced through a long 14 F sheath via the left femoral vein. The robotic catheter was steered along the Jwire to enter the left atrium. Intra-cardiac echocardiography was not used. The robotic sheath was steered into the left ventricle with the outer sheath of the Artisan positioned within the left atrium to support access to all parts of the left ventricle. A bipolar voltage map was created at standard scar settings. The Navistar Catheter was used for mapping the ventricle in all robotic cases. The Hansen system's integrated contact force feature, Intellisense™, was used for contact force feedback initially, and latter cases used the Navistar SmartTouch™ catheter (Biosense Webster Inc) instead. VT was initiated using programmed electrical stimulation from two sites with a basic drive cycle of 600 and/or 400 ms and up to three extrastimuli. In patients with haemodynamically tolerated VT, an activation map during VT was also created.
In the manual cases, access to the left ventricle was gained via a trans-septal puncture or retrograde approach depending on the location of scar. The Navistar catheter was used for mapping the ventricle in all manual cases.
Ablation strategy and settings
In stable VT cases, the CARTO™ activation maps were combined with conventional entrainment manoeuvers to define the target ablation sites, ideally at sites with mid diastolic potentials. For poorly tolerated VT, the voltage map was used to perform substrate ablation using one or more of the following; local capture with a 12/12 pacemap of the clinical or induced VT [19] , scar border location [20] , presence of a late potential [21] , or completion of a linear lesion [22] , as has been previously described. All patients undergoing robotic procedures in our unit using irrigated tip radiofrequency (RF) applications were limited to 30 W at 60 s with a flow rate of 17 ml/min and a temperature limit of 40°C. In the manual group, power output and delivery time was at the discretion of the operator. ICD programming post procedure was left unchanged.
Statistical analysis
Categorical variables were expressed as percentages. Continuous variables were expressed as mean±1 standard deviation for parametric data and/or median±inter-quartile range for non-parametric data. Paired nonparametric data were analysed using the Wilcoxon Signed Ranks test for non-parametric data. Unpaired continuous variables were analysed using a student's t test for parametric data and Mann-Whitney U test for non-parametric data. Fisher's exact test was used for categorical data. A value of p ≤ 0.05 was considered significant.
Results
Patients
Sixty patients underwent scar-related VT ablation during the study period. Figure 1 illustrates the number of patients within each exclusion criteria. This included 18 patients with nonischemic cardiomyopathy and 9 patients involved in a concurrent VT ablation trial that commenced during this interval in our institution. Two patients presented with VT below the device detection zone. Two patients had their ICD implanted post-ablation. The procedure was abandoned in 3 patients owing to trans-septal puncture-related complication. This included 1 patient who was a planned robotic procedure.
Of the remaining 26 patients, 12 underwent robotically guided post infarct VT ablation. The majority of patients were male (9/12, 75 %) with a mean age of 70.8±5.5 years at the time of the procedure. Forty-two percent (5/12) had diagnosed essential hypertension and 50 % (6/12) type II diabetes mellitus. The mean body mass index (BMI) was 29.0 ± 5.3 kg/m2. Patients had significantly impaired left ventricular function (28±14 %) and 67 % (8/12) had undergone coronary artery bypass grafting (CABG) with the remainder having undergone percutaneous coronary intervention (PCI). Fortytwo percent (5/12) were biventricular paced prior to the procedure.
Of the 14 patients who underwent manually guided ablation, 2 were followed up externally and excluded from the study. There was no significant difference in baseline characteristics and comorbidities between the remaining 12 manually ablated patients and the robotic group (Table 1) .
Pre-procedural therapy burden
The Sensei robotic system was often considered for ablation in those who had failed manual procedures and those presenting urgently with multiple ICD therapies/ storm. In those who failed manual procedures, the coronary angiograms were also reviewed for consideration of intracoronary ethanol.
A total of 9/12 robotic ablations (75 %) were undertaken in those presenting urgently, whereas only 4/12 (33 %) were as such in the manual arm (p=0.1). Four of the 12 (33 %) patients had undergone failed manual procedures compared to 1/12 (8 %) in the manual group undergoing a redo ablation (p = 0.32). A numerically higher median pre-ablation therapy burden was evident in the robotic arm (32 (5-400 IQR)) as compared to the manual arm (14 (10-25 IQR)) (p=0.49). 
Procedural data
In the cohort that underwent robotic VT ablation, 2.4±1.9 different VT morphologies were induced in each patient.
Mapping and ablation was performed in VT in 4 patients. Eight patients underwent substrate ablation only for unstable or non-sustained VT. Scar and ablation lesions were located around the anterior wall (including anterolateral and anteroseptal walls) in 4 patients, around the inferior wall (including inferoseptal and inferolateral walls) in 4 patients and apically (including 2 apical aneurysms) in 4 patients. All areas could be reached by robotic manipulation, and procedures were all completed robotically. An average of 35±25 RF applications were delivered with a maximum temperature of 38.3±2.4°C, power of 29.6±2.7 W and duration of 59.4± 3.4 s.
The intra-procedural data for both robotic and manual groups are summarised in Table 2 
Acute and long-term outcomes
Robotic arm
A comparison between the acute and long-term procedural outcomes between the robotic and manual groups is detailed in Table 3 . Following programmed ventricular stimulation at the end of the procedure, 6/12 (50 %) had no VT inducible (group A), 5/12 (42 %) had non-clinical VT only (group B) and 1/12 (8 %) had clinical VT inducible (group C). Six of the 12 (50 %) were maintained on amiodarone post procedure. Patients were followed up for a mean of 24.1±19.1 months. Data was available from patient attendances or ICD downloads from an average of 6.8±3.9 device interrogations. The total therapy burden (ATP+shocks) fell to a median of 3.5 (1-11) events. The calculated averaged 6-month post procedural therapy burden fell significantly to a median of 2.5 (0-11) (p= 0.015). This represented a 95 % therapy burden reduction. Three of the 12 (25 %) patients required a further ablation procedure during this follow-up period. Figure 2 demonstrates pre-and post-ablation therapy burdens for each robotic patient averaged over 6 months. Within Group A (non-inducible 1-6), 3/6 (50 %) patients had already undergone at least 2 previous manual ablations. This included Bpatient-3^, who was referred for robotic ablation owing to multiple ICD shocks despite 3 previous manual ablation procedures and maximal antiarrhythmic therapy (including amiodarone and mexiletine). Figure 3a , b shows fluoroscopic views of the ablation catheter at the apical septum. Ablation at this site successfully terminated the clinical VT (Fig. 3c) . Over more than 3 years of follow-up, no ICD therapies have been detected. This also included Bpatient-4^who presented with ICD storm on a background of 1501 appropriate ICD therapies (majority ATP). Ablation targeted the anterolateral wall. The patient remained therapy free for 120 days and has experienced only 10 therapies over more than a 4-year follow-up period. This also included Bpatient-2^who presented with ICD storm. Following mexiletine administration, VT could not be induced in the lab; hence, a substrate guided approach targeting the basal inferoseptum was performed. Having remained therapy free for 2 months, the patient represented in storm and underwent a surgical ablation following which she remained therapy free for 2 years, till she eventually expired from end stage heart disease [18] .
Within Group B (non-clinical VT only 8-12), Bpatient-7ê xperienced 11 appropriate ICD therapies (including 2 shocks) over the preceding 2 months. Seven VT morphologies were inducible in the lab-only 1 matched the documented pre-procedural VT and was inducible from the start. Six out of 7 VT's, including the clinical VT were successfully ablated to non-inducibility. Over more than 3 years of follow-up, this patient has had only 1 appropriate ATP episode. Patient 10 was admitted with incessant tolerated VT that was non-paceterminable and refractory to electrical cardioversion. The clinical VT was mapped towards the LV apex, including an aneurysmal component and terminated with ablation. A second VT was not eliminated but was pace-terminable at the end of the procedure. Over a 29-month follow-up, this patient has had only 1 appropriate ATP episode. Patient 11 presented with ICD storm refractory to amiodarone and mexiletine, on a background of 1557 appropriate ICD therapies. Five VT's, including the clinical VT, were induced in the lab, and ablation was targeted towards the apical inferior territory. Four out of 5 VT's, including the presumed clinical VT, were successfully ablated to non-inducibility. The remaining VT was not haemodynamically tolerated requiring electrical cardioversion. The patient, however, represented at month 11 and 13 with VT and underwent manual VT ablation procedures on each occasion. VT continued to occur; however, owing to a post procedural dense stroke after the 3rd ablation, no further interventional approaches were considered. The patient expired at month 26 from end stage heart disease. Group C (Clinical VT inducible) included patient 12 alone, who presented with ICD storm on a background of 561 ICD therapies. Two inducible VT morphologies were inducible in the lab, both of which were associated with haemodynamic instability. Ablation was performed by pace-mapping and substrate modification, however, despite multiple ablation lesions, VT 1 was still inducible. The procedure was terminated due to periods of haemodynamic instability and inability to find any further perfect pace-mapping sites in the region of interest. The patient experienced only 4 ATP's over 7-month follow-up and expired thereafter from end stage heart disease. The intra-procedural and long-term outcomes for each patient have been categorised per group and summarised in Table 4 . Figure 2 demonstrates pre-and post-ablation therapy burdens for each manual patient averaged over 6 months. The intra-procedural and long-term outcomes for each patient have been categorised per group and summarised in Table 5. 3.5 Procedure-related complications and death There were no peri-procedural complications related to ablation delivery in either of the groups in this study. The 30-day procedural mortality was nil in both arms. In the robotic group, 4/12 (33 %) patients died during this follow-up interval an average 16.0±12.2 months remote of the procedure. Three died from end stage heart failure and 1 died following a stroke. In the manual group, 4/12 (25 %) patients died an average 15.5±7.0 months remote of the procedure. Three died from Fig. 3 a RAO view and b LAO view of the ablation catheter in the LV apical septum. c Ablation at this site lead to VT termination. This patient had undergone 3 previous manual VT ablations prior to a robotic approach-he has been therapy free for over 3 years of follow-up Table 4 Pre, intra and post procedural data for each patient in the robotic group A anterior, AL anterolateral, Ap apical, IL inferolateral, IS inferoseptum, L lateral, abl ablations, Amio amiodarone, ICD implantable cardioverter defibrillator, Rx=treatment (ATP (anti-tachycardia pacing)+ shocks), VT CL ventricular tachycardia cycle length end stage heart failure and 1 died from mitral valve endocarditis.
Manual arm
Discussion
In this study, we have demonstrated both the feasibility and safety of using the Hansen Sensei® Robotic System in performing LV endocardial mapping and ablation in 12 patients who underwent post infarct scar-related VT ablation. The robotic system was often utilised in patients presenting urgently with multiple ICD events/storm and those who had recurrence of VT despite a previous ablation procedure. Robotic VT ablation resulted in a 95 % reduction in total ICD therapy burden (ATP+shocks) compared over a 6-month averaged interval (p=0.015). We compared our acute and long-term robotic outcome data with manual cases over a similar time period. Despite a potentially more complex arrhythmic substrate in the robotic arm, the acute and long-term procedural outcomes between the two groups were similar. The clinical VT was noninducible in all but 1 patient in both arms at the end of the case and the total post procedural ICD therapy burden fell significantly in both arms, to a median of 2.5 (0-11) episodes in the robotic and 1 (0-5) in the manual (p=0.60).
We intentionally reduced the power delivery during robotic ablation to no more than 30 W and delivered each lesion for no more than 60 s. This was based on previous animal studies where, at 45 W, charring, popping and perforation were seen [23] . As there was no restriction in the manual arm, both power output and duration were significantly higher for each ablation lesion delivered. The only other case series of robotic guided VT ablation allowed for a higher power output (50 W) and also demonstrated a significant reduction in the frequency of patient VT episodes [17] . The absence of any acute procedural complications directly attributable to the robotic system or during ablation in both studies is notable. The endpoint of non-inducibility of clinical VT is always sought, but targeting non-clinical inducible VT is often a decision based on the riskbenefit decision made by the operator based on the clinical status of the patient and will also depend on the aggressiveness of the induction protocol. Therefore, outside a fully protocolized randomised study, it is difficult to judge whether difference in procedure duration are due to the nature of the induction method or the endpoints that were sought.
The mean procedure duration and fluoroscopic times in the robotic arm were greater than in the manual arm. This was not the result of the mapping time which was similar. There are additional steps in a robotic procedure which include the introduction of a 14 F femoral long sheath, advancing the Artisan sheath to the right atrium, navigation of the catheter and Artisan sheath across the trans-septal puncture site and repositioning the outer sheath remotely during manipulation within the LV. Although non-significant, there were more VTs induced in the robotic arm implying more complex procedures in the robotic group.
We found movement of the ablation catheter within the left ventricle using the Hansen robotic sheath easier than manual manipulation of the ablation catheter within a deflectable sheath particularly for maintaining stability during RF delivery. Manoeuvrability around the papillary muscles was not more difficult with robotic ablation and there were no papillary muscle-related complications. Reaching the outflow tract and mitral annulus required adjustment of the outer sheath and torque settings so that the inner sheath turned back on itself, but this was still easier to do robotically than manually and, more importantly, with greater stability.
Several studies have reported only long-term freedom from any VT recurrence post-ablation as a marker of success [24] . VT ablation alters the existing substrate at the time of the procedure without influencing the progression of the underlying disease. Recurrence of VT during long-term follow-up may well be associated with disease progression through time, independent of the ablation procedure [25] . This outcome measure is particularly useful in studies of early ablation where many control patients do not receive any therapy. However, in this study, our patients had advanced disease with a high burden of successful ATP and reduction of therapy burden was a primary goal. Other studies have also reported overall reduction in ICD therapy burdens as a reflection of long-term success. Caution must be reserved in making comparisons with other studies owing to differences in ICD programming and use of antiarrhythmics post procedure. The Thermocool VT ablation Trial [26] and Euro VT study [27] both describe pre and post ICD therapy burdens in a cohort of patients with severe left ventricular impairment undergoing conventional VT ablation secondary to remote myocardial infarction. Both studies were large multicentre studies that described the effectiveness of saline-irrigated catheter technology in VT ablation with electro-anatomic mapping systems, an approach we used in all cases. Ablation of all inducible VTs was accomplished in 49 % of the 231 patients in the Thermocool trial. In our robotic cohort, complete noninducibility was seen in 50 %. The Euro VT study witnessed 81 % acute procedurally success in the 63 patients included, though some patients required 2 procedures. Of the 142 patients with ICD's that survived to 6 months in the Thermocool study, median VT episodes were reduced from 11.5 to 0, which was similar to our manual group. Although 47 % of patients experienced VT recurrence within this interval, the frequency of VT was reduced by >75 % in 67 % of patients. VT recurrence in Euro VT was also high at 49 % at 12 months, though mean ICD therapies fell from 60±70 pre-ablation to 14±15 6-months post-ablation (p=0.02). Mortality rates at 1 year were 8 and 18 %, respectively. We witnessed 33 % mortality at 2-year average follow-up in both the robotic and manual arms. In summary, outcomes in both these large ablation studies were similar to our robotic cohort. Furthermore, power outputs in both studies averaged 45 W. Fluoroscopy times and procedural durations in both studies were similar to our robotic cohort; however, the operators using the robotic approach had the benefit of being remote from the X-ray tube for the majority of the procedure with minimal radiation.
Limitations
The data presented is a small series from a single centre where cases were performed by experienced operators. Larger, randomised studies will be required to further understand the clinical utility of this approach over manual ablation. A prospective, multicentre, randomised study (ERASE VT: NCT01182389) comparing robotic-guided catheter ablation against medical therapy is on-going.
Conclusions
We have demonstrated that radiofrequency ablation of scarrelated VT using the Hansen Sensei® X Robotic Catheter System is feasible with good long-term outcomes, and this includes patients who have failed manual ablations and presented acutely with multiple ICD therapies/storm. Despite a higher pre-procedural therapy burden, when compared to a series of patients who underwent manual guided ablation, acute and long-term outcomes were similar. Authors contributions VL contributed data analysis/interpretation, statistics and drafting article. SJC contributed data analysis/interpretation, statistics and drafting article and is joint first author. MKW contributed data analysis/interpretation and drafting article. MSS contributed data analysis/interpretation and statistics. IJW, NWL, PBL, ZW, SH, DL, NSP and DWD contributed data collection and approval of article. PK contributed concept/design, critical revision of article and approval of article.
